The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Extended results of the Alzheimer's disease anti‐inflammatory prevention trial
Open accessAbstract
Background: Epidemiologic evidence suggests that nonsteroidal anti‐inflammatory drugs (NSAIDs) delay onset of Alzheimer's dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer's Disease Anti‐inflammatory Prevention Trial (ADAPT) randomized 2528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments were terminated. During the treatment interval, 32 cases of AD revealed increased rates in both NSAID‐assigned groups. Methods: We continued the double‐masked ADAPT protocol for 2 additional years to investigate incidence of AD (primary outcome). We then collected cerebrospinal fluid (CSF) from 117 volunteer participants to assess their ratio of CSF tau to Aβ 1‐42. Results: Including 40 new events observed during follow‐up of 2071 randomized individuals (92% of participants at treatment cessation), there were 72 AD cases. Overall, NSAID‐related harm was no longer evident, but secondary analyses showed that increased risk remained notable in the first 2.5 years of observations, especially in 54 persons enrolled with cognitive impairment––no dementia (CIND). These same analyses showed later reduction in AD incidence among asymptomatic enrollees who were given naproxen. CSF biomarker assays suggested that the latter result reflected reduced Alzheimer‐type neurodegeneration. Conclusions: These data suggest a revision of the original ADAPT hypothesis that NSAIDs reduce AD risk, as follows: NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 2 to 3 years. Thus, treatment effects differ at various stages of disease. This hypothesis is consistent with data from both trials and epidemiological studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
(1987) · PubMed · Cited by 2,657
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 13×
“We then collected cerebrospinal fluid (CSF) from 117 volunteer participants to assess their ratio of CSF tau to Ab1-42.”
BackgroundInfluentialLife and Death of Neurons in the Aging Brain
Morrison, J. H., & Hof, P. R. (1997) · Science · doi:10.1126/science.278.5337.412 · Cited by 1,344
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
García Rodríguez, L., & Jick, H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91843-0 · Cited by 975
The neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“CSF tau increases in patients with AD, and in thosewith prodromal AD symptoms [26], whereas Ab1-42 is known to decline during the development of AD [27].”
BackgroundGreen, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643
Self-citationCore candidate neurochemical and imaging biomarkers of Alzheimer's disease
Hampel, H., Bürger, K., Teipel, S. J., Bokde, A. L. W., Zetterberg, H., & Blennow, K. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.08.006 · Cited by 532
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498
A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402 · cited 1×
“Even in patients with milder cognitive symptoms, incidence of AD was found to increase in those who received the cyclooxygenase-2(COX-2)-selective NSAID rofecoxib [12].”
BackgroundChoi, S.-H., Aid, S., & Bosetti, F. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.01.002 · Cited by 402
Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 397
Self-citationMiller, S. L., Celone, K., DePeau, K., Diamond, E., Dickerson, B. C., Rentz, D., Pihlajamäki, M., & Sperling, R. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706818105 · Cited by 382
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Cyclooxygenases and the Central Nervous System
Kaufmann, W. E., Andreasson, K. I., Isakson, P. C., & Worley, P. F. (1997) · Prostaglandins · doi:10.1016/s0090-6980(97)00128-7 · Cited by 285
Weggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V., Fauq, A., Golde, T. E., & Koo, E. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303592200 · Cited by 280
CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment: A follow-up study
Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 279
Self-citationKotilinek, L. A., Westerman, M. A., Wang, Q., Panizzon, K., Lim, G. P., Simonyi, A., Lesne, S., Falinska, A., Younkin, L. H., Younkin, S. G., et al. (2008) · Brain · doi:10.1093/brain/awn008 · Cited by 220
Self-citationSafety and Acceptability of the Research Lumbar Puncture
Peskind, E. R., Riekse, R., Quinn, J. F., Kaye, J., Clark, C. M., Farlow, M. R., DeCarli, C., Chabal, C., Vavrek, D., Raskind, M. A., et al. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000194014.43575.fd · Cited by 193
ADAPT Research Group (2006) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0010033 · Cited by 176
Zahs, K. R., & Ashe, K. H. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.05.004 · Cited by 175
Self-citationAβ Oligomers Induce Neuronal Cell Cycle Events in Alzheimer's Disease
Varvel, N. H., Bhaskar, K., Patil, A. R., Pimplikar, S. W., Herrup, K., & Lamb, B. T. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2441-08.2008 · Cited by 158
Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease
Soininen, H. S., West, C. R., Robbins, J. L., & Niculescu, L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000096588 · Cited by 144
Prostanoids, not reactive oxygen species, mediate COX‐2–dependent neurotoxicity
Manabe, Y., Anrather, J., Kawano, T., Niwa, K., Zhou, P., Ross, M. E., & Iadecola, C. (2004) · Annals of Neurology · doi:10.1002/ana.20078 · Cited by 139
Szekely, C. A., Green, R. C., Breitner, J. C. S., Østbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000313933.17796.f6 · Cited by 121
Self-citationFree radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models
Sonnen, J. A., Breitner, J. C. S., Lovell, M. A., Markesbery, W. R., Quinn, J. F., & Montine, T. J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.04.022 · Cited by 113
Self-citationAlzheimer's Disease Anti‐Inflammatory Prevention Trial: Design, methods, and baseline results
ADAPT Research Group (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.09.004 · Cited by 110
Biomarkers for cognitive impairment and dementia in elderly people
Sonnen, J. A., Montine, K. S., Quinn, J. F., Kaye, J. A., Breitner, J. C. S., & Montine, T. J. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70162-5 · Cited by 84
Self-citationDouble placebo design in a prevention trial for Alzheimer's disease
Martin, B. K., Meinert, C. L., & Breitner, J. C. S. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(01)00189-1 · Cited by 71
Self-citationKojo, H., Fukagawa, M., Tajima, K., Suzuki, A., Fujimura, T., Aramori, I., Hayashi, K.-I., & Nishimura, S. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.93.347 · Cited by 44
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Cited by
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Self-citationImmune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Neuroinflammation: The role and consequences
Lyman, M., Lloyd, D. G., Ji, X., Vizcaychipi, M. P., & Ma, D. (2014) · Neuroscience Research · doi:10.1016/j.neures.2013.10.004 · Cited by 730
Implications of sleep disturbance and inflammation for Alzheimer's disease dementia
Irwin, M. R., & Vitiello, M. V. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30450-2 · Cited by 578
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
Metadata
- Authors
- Breitner, J. C., Baker, L. D., Montine, T. J., Meinert, C. L., Lyketsos, C. G., Ashe, K. H., Brandt, J., Craft, S., Evans, D. E., Green, R. C., Ismail, M. S., Martin, B. K., Mullan, M. J., Sabbagh, M., & Tariot, P. N.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-07
- Volume
- 7
- Issue
- 4
- Pages
- 402-411
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W1977585036
- Cited by
- 328
- References
- 36
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.